Factor VIII Inhibitor (Porcine)
Description:
Inhibitors to coagulation Factor VIII (FVIII) are antibodies that may occur in 10-15% of patients with congenital Haemophilia A. An autoimmune response to endogenous FVIII may rarely occur leading to acquired Haemophilia A. The use of non-human FVIII replacement therapy may be clinically indicated in this instance. The Nijmegen Bethesda assay has been modified to measure porcine FVIII recovery values following incubation of test plasma with porcine reference standand. One unit of inhibitor is defined as the amount that will neutralise 50% of the reference plasma containing 100% porcine FVIII after a 2 hour incubation.
This test is not currently included in the laboratory's UKAS scope of accreditation to ISO15189:2012.
This test is not currently included in the laboratory's UKAS scope of accreditation to ISO15189:2012.
Clinical details:
Recombinant porcine Factor VIII may be used to treat patients with inhibitors, particularly in acquired Haemophilia A. The use of a porcine FVIII reference standard in the Bethesda assay allows the detection of inhibitory activity specific to the porcine FVIII protein.
Reference range:
Not detected
Synonyms or keywords:
Obizur
Units:
NBU/mL
Department:
Location:
Last updated: 05/11/2021
